Security key
98420N105
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
CUSIP: 98420N105
Q4 2017 13F Holders as of 31 Dec 2017
- Type / Class
- Equity / Common Shares
- Shares outstanding
- 92,799,600
- Total 13F shares
- 9,156,573
- Share change
- -165,156
- Total reported value
- $25,870,113
- Price per share
- $2.83
- Number of holders
- 31
- Value change
- -$498,226
- Number of buys
- 13
- Number of sells
- 8
Report period
Q4 2017
Institutions
31
Top holders
10
XENE full security history
Newer quarter: Q1 2018
Previous quarter: Q3 2017
Xenon Pharmaceuticals Inc. SEC filings
Xenon Pharmaceuticals Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420N105
Recent filing periods:
Top shareholders of XENE - Xenon Pharmaceuticals Inc. - Common Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BVF INC/IL |
13F
|
Company |
3.9%
|
3,588,830
|
$10,587,000 | — | 30 Sep 2017 | |
| Capital World Investors |
13F
|
Company |
1.5%
|
1,429,000
|
$4,216,000 | — | 30 Sep 2017 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.68%
|
634,812
|
$1,873,000 | — | 30 Sep 2017 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.48%
|
449,284
|
$1,325,000 | — | 30 Sep 2017 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.41%
|
377,695
|
$1,114,000 | — | 30 Sep 2017 | |
| Invesco Private Capital, Inc. |
13F
|
Company |
0.4%
|
375,784
|
$1,109,000 | — | 30 Sep 2017 | |
| Tekla Capital Management LLC |
13F
|
Company |
0.38%
|
350,000
|
$1,033,000 | — | 30 Sep 2017 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.33%
|
310,179
|
$915,000 | — | 30 Sep 2017 | |
| SABBY MANAGEMENT, LLC |
13F
|
Company |
0.33%
|
307,600
|
$907,000 | — | 30 Sep 2017 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.3%
|
275,000
|
$811,000 | — | 30 Sep 2017 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.25%
|
228,029
|
$673,000 | — | 30 Sep 2017 | |
| K2 PRINCIPAL FUND, L.P. |
13F
|
Company |
0.18%
|
164,510
|
$485,000 | — | 30 Sep 2017 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.17%
|
156,400
|
$461,000 | — | 30 Sep 2017 | |
| Artal Group S.A. |
13F
|
Company |
0.16%
|
150,000
|
$443,000 | — | 30 Sep 2017 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.12%
|
109,559
|
$323,000 | — | 30 Sep 2017 | |
| J. Goldman & Co LP |
13F
|
Company |
0.08%
|
72,400
|
$214,000 | — | 30 Sep 2017 | |
| State of New Jersey Common Pension Fund D |
13F
|
Company |
0.07%
|
65,000
|
$192,000 | — | 30 Sep 2017 | |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM |
13F
|
Company |
0.06%
|
55,000
|
$162,000 | — | 30 Sep 2017 | |
| SCOTIA CAPITAL INC. |
13F
|
Company |
0.06%
|
54,371
|
$160,000 | — | 30 Sep 2017 | |
| David M. Knott |
13F
|
Individual |
0.05%
|
45,000
|
$133,000 | — | 30 Sep 2017 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.04%
|
41,173
|
$121,000 | — | 30 Sep 2017 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.02%
|
21,700
|
$65,000 | — | 30 Sep 2017 | |
| NJ State Employees Deferred Compensation Plan |
13F
|
Company |
0.02%
|
20,000
|
$59,000 | — | 30 Sep 2017 | |
| Leith Wheeler Investment Counsel Ltd. |
13F
|
Company |
0.02%
|
16,075
|
$47,000 | — | 30 Sep 2017 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.01%
|
9,226
|
$27,000 | — | 30 Sep 2017 | |
| INTERWEST VENTURE MANAGEMENT CO |
13F
|
Company |
0.01%
|
8,293
|
$24,000 | — | 30 Sep 2017 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0%
|
3,280
|
$10,000 | — | 30 Sep 2017 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
2,464
|
$7,000 | — | 30 Sep 2017 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
700
|
$2,000 | — | 30 Sep 2017 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
325
|
$1,000 | — | 30 Sep 2017 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
40
|
$118 | — | 30 Sep 2017 |
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Shares (XENE) as of Q4 2017
As of 31 Dec 2017,
Xenon Pharmaceuticals Inc. - Common Shares (XENE) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,156,573 shares.
The largest 10 holders included
BVF INC/IL, Capital World Investors, ORBIMED ADVISORS LLC, Schonfeld Strategic Advisors LLC, DAFNA Capital Management LLC, Tekla Capital Management LLC, Invesco Private Capital, Inc., SABBY MANAGEMENT, LLC, Point72 Asset Management, L.P., and Alyeska Investment Group, L.P..
This page lists
31
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2017 vs Q3 2017 Across Filers
Q3 2017 holders
31
Q4 2017 holders
31
Holder diff
0
| Investor | Q3 2017 Shares | Q4 2017 Shares | Share Diff | Share Chg % | Q3 2017 Value $ | Q4 2017 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.